Comparative Pharmacology
Head-to-head clinical analysis: TRIUMEQ versus TRIUMEQ PD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIUMEQ versus TRIUMEQ PD.
TRIUMEQ vs TRIUMEQ PD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIUMEQ is a fixed-dose combination of dolutegravir, an HIV integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting integration of viral DNA into host cell DNA, and abacavir/lamivudine, nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase.
Triumeq PD is a combination of abacavir (a nucleoside reverse transcriptase inhibitor, NRTI) and dolutegravir (an integrase strand transfer inhibitor, INSTI). Abacavir is phosphorylated to carbovir triphosphate, which inhibits HIV-1 reverse transcriptase by competing with natural dGTP and causing DNA chain termination. Dolutegravir inhibits HIV-1 integrase by binding to the integrase active site and blocking strand transfer, preventing integration of viral DNA into host DNA.
One tablet (abacavir 600 mg, dolutegravir 50 mg, lamivudine 300 mg) orally once daily.
One tablet (abacavir 600 mg / dolutegravir 50 mg / lamivudine 300 mg) orally once daily.
None Documented
None Documented
Abacavir: 1.5 h (intracellular carbovir-TP 20 h). Dolutegravir: 14 h (inhibits its own metabolism). Lamivudine: 13-19 h (intracellular lamivudine-TP 16-19 h). Clinical context: Once-daily dosing due to long intracellular half-lives.
Abacavir: 1.5-2.0 hours. Dolutegravir: 14 hours (single dose), 11-13 hours (steady state). Lamivudine: 13-19 hours. Clinical context: Dolutegravir half-life supports once-daily dosing; abacavir rapid elimination requires twice-daily dosing.
Abacavir: 83% renal (unchanged and metabolites), 16% fecal. Dolutegravir: 64% fecal (unchanged), 31% renal (metabolites, <1% unchanged). Lamivudine: ~70% renal (unchanged).
Abacavir: 83% renal (unchanged and metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Dolutegravir: 64% fecal (unchanged), 32% renal (unchanged and glucuronide conjugate). Lamivudine: 70% renal (unchanged).
Category C
Category C
Integrase Strand Transfer Inhibitor (INSTI) Combination Antiretroviral
Integrase Strand Transfer Inhibitor (INSTI) Combination Antiretroviral